US FDA Approves Novo Nordisk Inc.’s VAGIFEM

Glenmark Pharmaceuticals announced that a generic version of Novo Nordisk Inc's VAGIFEM has been approved by the United States Food and Drug Administration.

According to IQVIA data of sales of the year July 2017 to 2018, Glenmark claims that Novo Nordisk Inc's VAGIFEM earned them a income of approx 286.3 million US dollars annually.

In New Delhi on 17^th September Glenmark Pharmaceuticals announced that a generic version of Novo Nordisk c's VAGIFEM used for treating a symptom of menopause manufactured by them has been approved by the United States Food and Drug Administration. Estradiol Vaginal Inserts USP, 10 mcg has received confirmed permission by the US government.

According to IQVIA data of sales of the year July 2017 to 2018, Glenmark claims that Novo Nordisk Inc's VAGIFEM earned them a income of approx 286.3 million US dollars annually.

The company Glenmark Pharmaceuticals for now offers 139 authorized products in the US market and 61 new medicines that seek approval from the United States Food and Drug Administration.

The stocks of the company were traded by the profit of 0.65 percentage at rupees 694.40 on the BSE.